Sinopharm And Tianjin Pharmaceutical Sign Strategic Collaboration Agreement
This article was originally published in PharmAsia News
Sinopharm and Tianjin Pharmaceutical have signed a collaborative agreement whereby Sinopharm will invest in the latter's subsidiary Jinkang Pharmaceutical and jointly forge the nation's antibiotic production base. Sinopharm will support the implementation of Tianjin Pharmaceutical's globalization strategy, while Sinopharm Medicine Holding Tianjin and Tianjin Taiping (Group) will set up a new firm to develop a modernized medical logistics platform. The strategic agreement will facilitate the two companies to improve their innovation capability, integrate resources and reduce purchase and storage costs to enhance their competitiveness and expand market share. (Click here for more - Chinese Language)
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.